HomeMOLN • NASDAQ
Molecular Partners AG
$4.33
0.46%
+0.020 Today
Mar 14, 8:30:00 PM UTC-4 · USD · NASDAQ · Disclaimer
Financials
Income Statement
-10M0
Revenue
Net Income
Revenue
Net income
(CHF)Dec 2024Y/Y change
Revenue
0.00-100.00%
Operating expense
5.35M-7.37%
Net income
-11.23M43.22%
Net profit margin
Earnings per share
-0.30
EBITDA
-14.55M11.39%
Effective tax rate
-0.02%
050M100M150M
Total Assets
Total Liabilities
Total assets
Total liabilities
(CHF)Dec 2024Y/Y change
Cash and short-term investments
149.44M-20.04%
Total assets
158.53M-20.08%
Total liabilities
16.89M-22.95%
Total equity
141.64M
Shares outstanding
36.86M
Price to book
1.12
Return on assets
-23.65%
Return on capital
-25.90%
-2M-1M01M
Net Change in Cash
Net change in cash
(CHF)Dec 2024Y/Y change
Net income
-11.23M43.22%
Cash from operations
-13.20M17.47%
Cash from investing
-4.49M-123.10%
Cash from financing
15.30M5,234.56%
Net change in cash
-1.88M-72.29%
Free cash flow
-6.34M32.28%
US listed security
Previous close
$4.31
Day range
$4.33 - $4.35
Year range
$3.32 - $12.70
Market cap
171.62M USD
Avg Volume
2.62K
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Employees
159
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Main menu
Google apps